PMV Pharmaceuticals, Inc. (PMVP)

Add to research

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Company performance
Add to research
View more

Current Price

as of Jun 13, 2025

$1.08

P/E Ratio

N/A

Market Cap

$56.11M

Description
Add to research
View more

PMV Pharmaceuticals, Inc. is a precision oncology company, which engages in the discovery and development of small molecule, tumor-agnostic therapies targeting p53. The company was founded by Arnold J. Levine, David Henry Mac, and Thomas E. Shenk in March 2013 and is headquartered in Princeton, NJ.

Metrics
Add to research
View more

Overview

  • HQPrinceton, NJ
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerPMVP
  • Price$1.08-0.92%

Trading Information

  • Market cap$56.11M
  • Float84.21%
  • Average Daily Volume (1m)377,004
  • Average Daily Volume (3m)218,843
  • EPS-$1.17

Company

  • RevenueN/A
  • Rev growth (1yr)N/A
  • Net income-$17.44M
  • Gross marginN/A
  • EBITDA marginN/A
  • EBITDA-$21.53M
  • EV-$102.65M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B0.35
  • Debt/Equity0.69
Documents
Add to research
View more
SEC Filings
8-K (2025-06-09)
8-K (2025-05-09)
8-K (2025-03-03)
8-K (2024-11-07)
8-K (2024-08-08)
8-K (2024-06-07)
8-K (2024-05-09)
8-K (2024-02-29)
8-K (2024-01-18)
8-K (2024-01-05)
8-K (2023-11-09)
8-K (2023-10-12)
8-K (2023-10-11)
8-K (2023-08-09)
8-K (2023-06-09)
8-K (2023-05-10)
8-K (2023-04-28)
8-K (2023-03-01)
10-Q (2025-05-09)
10-Q (2024-11-07)
10-Q (2024-08-08)
10-Q (2024-05-09)
10-Q (2023-11-09)
10-Q (2023-08-09)
10-Q (2023-05-10)
10-K (2025-03-03)
10-K (2024-02-29)
10-K (2023-03-01)
Factset
Factset Business Description
Factset Street Account
PMV Pharmaceuticals reports Q3 EPS ($0.34) vs FactSet ($0.46) [7 est, ($0.56)-(0.43)] ($1.86, 0.00) (2023-11-09T13:10:41Z)
PMV Pharmaceuticals announces updated PC14586 Phase 1 data demonstrated anti-tumor activity across multiple solid tumor types with a TP53 Y220C mutation ($4.55, -0.20) (2023-10-12T16:34:26Z)